share_log

中国银河4月22日发布研报称，给予恒瑞医药（600276.SH）推荐评级。评级理由主要包括：1）创新成果持续兑现，驱动收入稳定增长；2）持续建设领先技术平台，打造优质创新产品。（每日经济新闻）

China Galaxy released a research report on April 22 stating that Hengrui Pharmaceutical (600276.SH) was given a recommended rating. The main reasons for the rating include: 1) continuous implementation of innovative achievements to drive steady revenue gr

Zhitong Finance ·  Apr 22 07:51
China Galaxy released a research report on April 22 stating that Hengrui Pharmaceutical (600276.SH) was given a recommended rating. The main reasons for the rating include: 1) continuous implementation of innovative achievements to drive steady revenue growth; 2) continuous construction of leading technology platforms to create high-quality innovative products. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment